Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN Imprimer: 0893-9675
ISSN En ligne: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.2018027641
pages 161-171

Immunotherapeutic Approaches to Head and Neck Cancer

Hassan Nasser
Department of Otolaryngology-Head and Neck Surgery, David Geffen School of Medicine
Maie St. John
UCLA Head and Neck Cancer Program, Jonsson Comprehensive Cancer Center, Ronald Reagan Medical Center, Los Angeles, CA, USA


Head and neck squamous cell carcinoma (HNSCC) is an immunosuppressive disease with multiple mechanisms to impair immune-mediated recognition and control of tumor cell proliferation and metastasis. Based on successes experienced with cancer immunotherapy in the treatment of other solid tumors, considerable efforts are underway to develop immunotherapeutics that can enhance the host antitumor response to HNSCC. Promising results in preclinical studies and early clinical trials have been reported, prompting the FDA to approve the use of the immune checkpoint PD-1 receptor antagonist pembrolizumab for the treatment of platinum-refractory recurrent or metastatic HNSCC in 2016. Ongoing clinical trials are investigating the use of various immunotherapies, such as vaccines, adoptive T-cell transfer, and immune modulating antibodies alone or in conjunction with traditional treatment modalities, to achieve more efficacious, more durable, and less toxic treatments. In this article, we provide a basic review of the role of the immune system in developing malignancy, and we discuss some notable mechanisms of immune evasion in HNSCC. We highlight current approaches and published clinical results of immunotherapy in the treatment of HNSCC.

Articles with similar content:

Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
Non-Major Histocompatibility Complex Rheumatoid Arthritis Susceptibility Genes
Critical Reviews™ in Immunology, Vol.31, 2011, issue 2
Saleh M. Ibrahim, Manfred Kunz
Druggable Targets in Pancreatic Adenocarcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Cristina Napoli, Stefania Nobili, Ida Landini, Gabriele Perrone, Enrico Mini, Renato Tassi
Nanostructured Delivery Systems: Augmenting the Delivery of Antiretroviral Drugs for Better Management of HIV/AIDS
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.32, 2015, issue 6
Sanaul Mustafa, Roopa S Pai, Gurinder Singh
Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Mengying Hong, Ren Sun, Jing Qian, Hongyu Deng, Shu Zheng, Kejun Tang, Yushen Du, Kefeng Ding, Musheng Zeng